Using KIR Genotyping to Improve Transplant Success
This interview examines the use of KIR genotyping during donor selection and its association with improved outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
In this video, Katy Rezvani, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the current treatment strategy and challenges for patients receiving an allogeneic hematopoietic stem cell transplant (HSCT), as well as evidence that points to the need to include killer cell immunoglobulin–like receptor (KIR) genotyping in the selection of donors to help reduce the risk of relapse.
Dr. Rezvani spoke on this topic as part of an education session at the 58th Annual Meeting of the American Society of Hematology, which was held last month in San Diego.
